BioSpace News Archive

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported pipeline and business progress and fourth quarter and full year 2021 financial results.

Bone replacement is a surgical procedure used to fix joints and bone damages caused due to severe orthopedic diseases and fractures. It is also performed for correction of deformities or as reconstruction to damaged or missing bones.

Elbow lesion are injuries that disrupt the cartilage and subjacent bone, and most commonly involve the capitellum. Factors that can result in elbow lesion include genetics, improper nutrition, and trauma.

Based on data published in the National Center for Biotechnology Information, an estimated incidence rate of Somatostatinoma is of 1/40,000,000 globally.

Patient lifts have proven to be useful for disabled persons as well as caregivers. Disabled and elderly individuals face mobility issues while performing their day-to-day tasks, even finding the process to be dangerous most of the time.

Heavy power surgical tools are devices activated by a power source and help in performing specific procedures during surgeries, such as adjusting biological tissue or gaining access to view an organ.

Surgical imaging is one of the revolutionary technology for optical imaging that is utilized for image guide surgical process.

Allergan Aesthetics, an AbbVie company, will join industry colleagues and healthcare providers from around the globe for the 20th edition of AMWC in Monaco, France.

IAMA Therapeutics announced a strategic collaboration with the IIT-Istituto Italiano di Tecnologia - where they will design and profile new classes of compounds targeting cation cotransporters in the CNS area.

ImmunoGen, Inc. announced that it has submitted a Biologics License Application under the accelerated approval pathway to the US Food and Drug Administration for mirvetuximab soravtansine monotherapy in patients with folate receptor alpha -high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic treatments.